Quantcast
Home > Quotes > IMMU
IMMU

Immunomedics, Inc. Common Stock (IMMU) Quote & Summary Data

$26.13
*  
0.13
0.5%
Get IMMU Alerts
*Delayed - data as of Jul. 20, 2018  -  Find a broker to begin trading IMMU now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 26.28 / $ 25.88
Share Volume
1,028,494
50 Day Avg. Daily Volume
2,876,934
Previous Close
$ 26
52 Week High / Low
$ 27.33 / $ 7.17
Market Cap
4,718,333,974
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
1,028,494
50 Day Avg. Daily Volume:
2,876,934

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.68

Trading Range

The current last sale of $26.13 is 264.44% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 26.28 $ 27.33
 Low: $ 25.88 $ 7.17

Company Description (as filed with the SEC)

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Our proprietary technologies allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, we have built a pipeline of six clinical-stage product candidates. Our most advanced product candidate is IMMU-132 (sacituzumab govitecan), an antibody-drug conjugate ("ADC") that has received Breakthrough Therapy Designation ("BTD") from the United States Food and Drug Administration ("FDA") for the treatment of patients with metastatic triple-negative breast cancer ("mTNBC") who have failed at least two prior therapies for metastatic disease.  ... More ...  

Risk Grade

Where does IMMU fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 26.06
Open Date:
Jul. 20, 2018
Close Price:
$ 26
Close Date:
Jul. 20, 2018

Consensus Recommendation

Analyst Info